Promega Launches NanoBRET™ Target Engagement Intracellular Kinase Assay, First to Quantitatively Measure Drug-Kinase Interactions in Live Cells
MADISON, WI USA (November 28, 2017) Promega Corporation’s new NanoBRET™ Target Engagement (TE) Intracellular Kinase Assay is the first assay to quantify inhibitor drug binding to kinase proteins inside live human cells, as demonstrated in the recent Cell Chemical Biology article, “Quantitative, Wide-spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement.”... Read more